Medtronic receives fda clearance for expanded indication of linq ii™ insertable cardiac monitor for use in pediatric patients ages 2 and older

The linq ii icm is the first continuous, long-term cardiac monitor cleared by fda for the pediatric patient population dublin , sept. 20, 2022 /prnewswire/ -- medtronic plc (nyse:mdt), a global leader in healthcare technology, today announced the linq ii™ insertable cardiac monitor (icm) system is the first-and-only icm to receive 510(k) clearance by the u.s. food and drug administration (fda) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.
MDT Ratings Summary
MDT Quant Ranking